Sartorius Stedim Biotech Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Rene Faber

Amministratore delegato

€790.0k

Compenso totale

Percentuale dello stipendio del CEO	68.4%
Mandato del CEO	1.7yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	8.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Rene Faber rispetto agli utili di Sartorius Stedim Biotech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	€161m
Jun 30 2024	n/a	n/a	€170m
Mar 31 2024	n/a	n/a	€255m
Dec 31 2023	€790k	€540k	€310m
Sep 30 2023	n/a	n/a	€460m
Jun 30 2023	n/a	n/a	€635m
Mar 31 2023	n/a	n/a	€717m
Dec 31 2022	€578k	€288k	€876m
Sep 30 2022	n/a	n/a	€681m
Jun 30 2022	n/a	n/a	€625m
Mar 31 2022	n/a	n/a	€559m
Dec 31 2021	€901k	€396k	€414m
Sep 30 2021	n/a	n/a	€523m
Jun 30 2021	n/a	n/a	€469m
Mar 31 2021	n/a	n/a	€398m
Dec 31 2020	€742k	€396k	€336m
Sep 30 2020	n/a	n/a	€299m
Jun 30 2020	n/a	n/a	€255m
Mar 31 2020	n/a	n/a	€254m
Dec 31 2019	€784k	€425k	€235m

Compensazione vs Mercato: La retribuzione totale di Rene ($USD 852.95K ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 5.18M ).

Compensazione vs guadagni: La retribuzione di Rene è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Rene Faber (49 yo)

1.7yrs

Mandato

€790,000

Compensazione

Dr. Rene Faber serves as Head of Bioprocess Solutions Division and Member of the Executive Board at Sartorius Aktiengesellschaft since January 01, 2019. He serves as Chief Executive Officer at Sartorius St...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Rene Faber	CEO & DIrector	5.7yrs	€790.00k	Nessun dato
Joachim Kreuzburg	Non-Executive & Non-Independent Chairman	17.4yrs	€693.15k	0.000010% € 1.8k
Lothar Kappich	Director	7.2yrs	€84.00k	0% € 0
Henri Riey	Director	17.4yrs	€56.00k	0.000010% € 1.8k
Pascale Boissel	Independent Director	5.7yrs	€93.00k	0% € 0
Anne-Marie Graffin	Lead Independent Director	9.6yrs	€91.00k	0.000010% € 1.8k
Susan Dexter	Independent Director	9.6yrs	€84.00k	0.000010% € 1.8k
Romaine Fernandes	Employee Representative Non - Executive Director	1.1yrs	Nessun dato	0% € 0

8.4yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 56S1 sono considerati esperti (durata media dell'incarico 8.4 anni).

Sartorius Stedim Biotech Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: €0.26 (vs €0.28 in 3Q 2023)

Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023)

Now 22% overvalued

Investor sentiment deteriorates as stock falls 16%

First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023)

Upcoming dividend of €0.69 per share

Dividend of €0.69 announced

New minor risk - Profit margin trend

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

First quarter 2023 earnings released: EPS: €1.21 (vs €2.93 in 1Q 2022)

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021)

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021)

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021)

Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021

Upcoming dividend of €1.26 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022

Sartorius Stedim Biotech S.A. Recommends Dividend

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022

Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020)

Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021

First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020)

Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021

Sartorius Stedim Biotech Increases Earnings Guidance for 2021

Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019)

Revenue misses expectations

New 90-day high: €416

New 90-day high: €366

Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS.

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o.

New 90-day high: €329

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021

New 90-day high: €313

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million.

New 90-day high - €303

New 90-day high - €273

Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR).

New 90-day high - €259

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media